BIOMAT Database Logo BIOMAT Database Logo

[Effects of high-dose methotrexate therapy on intestinal bacterial flora in children with acute lymphoblastic leukemia]. 2008

Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Department of Pediatrics, the First Affiliated Hospital, Kunming Medical College, Kunming 650032, China.

OBJECTIVE To investigate the effects of high-dose methotrexate (HDMTX) therapy on intestinal bacterial flora in children with acute lymphoblastic leukemia (ALL). METHODS Thirty-six children with ALL of pre-and post-HDMTX therapy and 36 control children were enrolled. The bacterial DNA in stool was extracted. The primers for Bacillus bifidus and Escherichia coli with the 16SrRNA/DNA sequence of bacteria were designed. The bacteria were identified through general PCR. The standard curve of both bacterial DNA was produced using a series of dilution of accurately quantified bacterial DNA. The unknown samples were measured by 16SrRNA/DNA-targeted PCR. The amount of stool Bacillus bifidus and Escherichia coli among 36 control children and 36 children with ALL of pre- and post-HDMTX therapy were obtained by using the standard curves. RESULTS Bacillus bifidus logarithmic absolute value of the first day before treatment, of third day after treatment, of seventh day after treatment in patients with ALL and the control was 7.24 +/- 0.33, 6.00 +/- 0.27, 6.59 +/- 0.33, and 9.49 +/- 0.41, respectively (P < 0.01). Escherichia coli logarithmic absolute value of the first day before treatment, of third day after treatment, of seventh day after treatment in patients with ALL and the control was 6.62 +/- 0.42, 5.96 +/- 0.42, 7.02 +/- 0.41, and 7.52 +/- 0.43, respectively (P < 0.01). The logarithm of the amount of stool Bacillus bifidus and Escherichia coli in control group was higher in ALL group (F = 739.61, 88.67, P < 0.01). There were significant difference (P < 0.01) in the logarithm of the amount of stool Bacillus bifidus and Escherichia coli between pre-therapy and post-therapy group. The logarithm of the bacterium was very low on third day after treatment, but gradually increased on the seventh day after treatment. CONCLUSIONS (1) HDMTX therapy has great effects on intestinal flora of Bacillus bifidus and Escherichia coli and significantly reduced the bacteria in children with ALL. (2) Probiotics had significantly decreased in ALL group than in control group.

UI MeSH Term Description Entries
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
March 2003, Cancer chemotherapy and pharmacology,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
[Clinical tolerance of high-dose methotrexate used in consolidation therapy in children with acute lymphoblastic leukemia].
January 2010, Przeglad lekarski,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.
January 2004, Pediatric hematology and oncology,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.
May 2005, AJNR. American journal of neuroradiology,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
[Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].
February 2008, Zhongguo shi yan xue ye xue za zhi,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
January 2005, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia.
April 2001, Medical and pediatric oncology,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
March 2008, Blood,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia.
January 1989, Medical and pediatric oncology,
Wu Yang, and Hua Liu, and Jing Duan, and Ying Zhang, and Yong-kun Huang, and Wen He, and Ping Lu, and Hai-lin Li
Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
December 2014, Pediatric blood & cancer,
Copied contents to your clipboard!